Recursion Pharmaceuticals vs Sutro Biopharma
RXRX and STRO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RXRX and STRO compare
Recursion Pharmaceuticals is the larger company, worth 11 times as much as Sutro Biopharma ($1.9B against $170M).
Recursion Pharmaceuticals grew revenue faster over the last twelve months (56.2% versus −56.3% for Sutro Biopharma).
Sutro Biopharma keeps more of each dollar of sales as profit, with a net margin of −395% compared with −697% at Recursion Pharmaceuticals.
Recursion Pharmaceuticals scores higher on the StockData Score (8 against 7 for Sutro Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RXRX | STRO |
|---|---|---|
| Size and price | ||
| Market cap | $1.9B | $170M |
| Share price | $3.59 | $10.26 |
| Change, 1 year | −20.4% | 27.3% |
| Change, 5 years | −81.9% | −94.2% |
| Beta (5Y) | 2.68 | 2.21 |
| Employees | 50 | 137 |
| StockData Score | ||
| Total score | 8 (better) | 7 |
| Valuation score | 1 | 1 |
| Growth score | 3 (better) | 1 |
| Performance score | 2 (better) | 0 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 28.2× | 3.7× (better) |
| P/B | 2.1× | – |
| FCF yield | −16.3% | – |
| Fair value | $3.23 | – |
| Margin of safety | −11.3% | – |
| Growth | ||
| Revenue growth (TTM) | 56.2% (better) | −56.3% |
| Revenue growth, 5Y average | 79.9% (better) | 19.1% |
| Profitability | ||
| Gross margin | 29.2% | – |
| Operating margin | −725% | −320% (better) |
| Net margin | −697% | −395% (better) |
| FCF margin | −458% | – |
| Return on equity | −48.7% | – |
| Return on invested capital | −102% | – |
| Financial health | ||
| Debt / equity | 0.01 | – |
| Interest coverage | −541.6× | – |
| Current ratio | 5.01 (better) | 3.32 |
| Altman Z-score | 0.05 (better) | −8.74 |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −11.4% | – |
| Shareholder yield | −11.4% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 67.6% | 99.4% |
| Held by insiders | 5.6% | 6.1% |
| Insider net buying, 12 months | −$7.4M | $0 (better) |
| Short interest, % of float | 28.2% | 14.5% |
Go deeper
- RXRX stock overview
- RXRX income statement
- RXRX valuation and score
- STRO stock overview
- STRO income statement
- STRO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.